✦ LIBER ✦

Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors

✍ Scribed by Dal Lago, L.; D'Hondt, V.; Awada, A.

Book ID: 125420422
Publisher: Alphamed Press
Year: 2008
Tongue: English
Weight: 230 KB
Volume: 13
Category: Article
ISSN: 1083-7159
DOI: 10.1634/theoncologist.2007-0233

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

584 Preclinical and Clinical Evaluation

584 Preclinical and Clinical Evaluation of the Combination of Sorafenib and Everolimus in Patients with Advanced Solid Tumors

✍ Ma, W.; Weekes, C.; Pawaskar, D.K.; Fetterly, G.; Messersmith, W.; Dy, G.; Strau 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

98 POSTER A Phase I study of sorafenib i

98 POSTER A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors

✍ A. Awada; T. Gil; K. Burk; J. Vanhamme; I. Mancini; T. Besse; E. Brendel; A. Mat 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Pharmacokinetic results of a phase I tri

Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors

✍ Erich Brendel; Matthias Ludwig; Chetan Lathia; Caroline Robert; Stanislas Ropert 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 367 KB

Phase I pharmacokinetic and pharmacodyna

Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors

✍ Simonelli, Matteo; Zucali, Paolo A.; Lorenzi, Elena; Rubino, Luca; De Vincenzo, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 585 KB

Clinical Trials Review: Molecular Target

Clinical Trials Review: Molecular Targeted Agents in Combination with Radiotherapy in Solid Tumors: A Pharmaceutical Industry Perspective

✍ Ataman, O.; Wedge, S.R.; Sambrook, S.J.; Wilks, C.; Taylor, A. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi